JILL JACOBSON, M.D.
Medical Practice at Gillham Rd, Kansas City, MO
License number
Missouri 104266
Category
Medical Practice
Type
Pediatric Endocrinology
Address
Address
2401 Gillham Rd, Kansas City, MO 64108
Phone
(816) 234-3000
Personal information
See more information about JILL JACOBSON at radaris.comName
Address
Phone
4532 Shoshone Trl, Saint Charles, MO 63304
4715 Flint Ridge Rd, Riverside, MO 64150
200 12Th St, Fulton, MO 65251
1703 Oak Cir, Blue Springs, MO 64014
1306 Rosemary Ln, Columbia, MO 65201
Organization information
See more information about JILL JACOBSON at bizstanding.comJill Jacobson MD
2401 Gillham Rd, Kansas City, MO 64108
Industry:
Pediatric Endocrinologist, Internist
Phone:
(816) 234-3000 (Phone)
Jill Diane Jacobson
Jill Jacobson MD
3101 Broadway Blvd #6, Kansas City, MO 64111
Categories:
Physicians & Surgeons
Phone:
(816) 234-1660 (Phone)
Professional information
See more information about JILL JACOBSON at trustoria.com
Dr. Jill Jacobson, Kansas City MO - MD (Doctor of Medicine)
Dr. Jill Jacobson, Kansas City MO - MD (Doctor of Medicine)
Specialties:
Pediatric Endocrinology
Address:
Childrens Mercy Hospital
2401 Gillham Rd, Kansas City 64108
(816) 234-3000 (Phone)
Kansas City
2401 Gillham Rd, Kansas City 64108
(816) 234-3000 (Phone), (913) 261-2090 (Fax)
2401 Gillham Rd, Kansas City 64108
(816) 234-3000 (Phone)
Kansas City
2401 Gillham Rd, Kansas City 64108
(816) 234-3000 (Phone), (913) 261-2090 (Fax)
Certifications:
Pediatric Endocrinology, 2003, Pediatrics, 1998
Awards:
Healthgrades Honor Roll
Languages:
English
Education:
Medical School
University of Miami / School of Medicine
Graduated: 1985
Chldns Hosp-U Wash
Nih
University of Miami / School of Medicine
Graduated: 1985
Chldns Hosp-U Wash
Nih
Jill D Jacobson, Kansas City MO
Jill D Jacobson, Kansas City MO
Specialties:
Pediatric Endocrinologist
Address:
3101 Broadway St, Kansas City, MO 64111
5808 W 110Th St, Leawood, KS 66211
2401 Gillham Rd, Kansas City, MO 64108
5808 W 110Th St, Leawood, KS 66211
2401 Gillham Rd, Kansas City, MO 64108
Education:
University of Miami, Miller School of Medicine - Doctor of Medicine*
National Institutes of Health-Clinical Center - Fellowship - Endocrinology*
Children's Hospital & Regional Medical Center - Residency - Pediatrics*
National Institutes of Health-Clinical Center - Fellowship - Endocrinology*
Children's Hospital & Regional Medical Center - Residency - Pediatrics*
Board certifications:
American Board of Pediatrics Sub-certificate in Pediatric Endocrinology (Pediatrics)*
Jill Diane Jacobson, Kansas City MO
Jill Diane Jacobson, Kansas City MO
Specialties:
Pediatrics, Pediatric Endocrinology, Endocrinology, Diabetes & Metabolism
Work:
Children's Mercy Hospital
2401 Gillham Rd, Kansas City, MO 64108 CMH Professional Group
1106 Saint Marys Rd, Junction City, KS 66441
2401 Gillham Rd, Kansas City, MO 64108 CMH Professional Group
1106 Saint Marys Rd, Junction City, KS 66441
Education:
University of Miami(1985)
Prevention Of Diabetes And Prolongation Of The Honeymoon Phase Of Diabetes By Administration Of Gnrh Antagonists
Prevention Of Diabetes And Prolongation Of The Honeymoon Phase Of Diabetes By Administration Of Gnrh Antagonists
US Patent:
2003004, Mar 6, 2003
Filed:
Jul 12, 2002
Appl. No.:
10/193862
Inventors:
Jill Jacobson - Kansas City MO, US
International Classification:
A61K038/10, A61K038/08
US Classification:
514/014000, 514/015000
Abstract:
A method for reducing the incidence or delaying the onset of diabetes in diabetes-susceptible mammals (e.g., mice, rats, humans) is provided wherein the mammals are treated with a gonadotropin-releasing hormone (GnRH) antagonist. Additionally, the present invention provides a method of prolonging the honeymoon phase and decreasing the rate of islet cell infiltration by lymphocytes by administration of a GnRH antagonist. Preferably, the antagonist is administered repeatedly over time by subcutaneous injection. Preferred antagonists include Acetyl--[2-Naphthyl]-D-Ala-D-p-Chloro-Phe--[3-Pyridyl]-D-Ala-Ser-N -[Nicotinoyl]-Lys-N -[Nicotinoyl]-D-Lys-Leu-N -[Isopropyl]-Lys-Pro-D-Ala-NH, Nal-Glu, Abarelix, Degarelix, and acetyl-D2Nal-D4CIPhe-D3Pal-Ser-Aph(Ac)-D-Aph(Ac)-Leu-Lys(lpr)-Pro-D-Ala-NH2.
Measurement Of G-Protein Mrna In The Diagnosis Of Growth Hormone Insufficiency
Measurement Of G-Protein Mrna In The Diagnosis Of Growth Hormone Insufficiency
US Patent:
2011011, May 12, 2011
Filed:
Apr 30, 2010
Appl. No.:
12/771377
Inventors:
Jill D. Jacobson - Kansas City MO, US
Mark Clements - Kansas City MO, US
Mark Clements - Kansas City MO, US
Assignee:
THE CHILDREN'S MERCY HOSPITAL - Kansas City MO
International Classification:
A61K 38/25, C12Q 1/68, A61P 5/06
US Classification:
514 112, 435 6
Abstract:
The present invention is directed towards a diagnostic test, treatment, and monitoring of treatment for growth hormone abnormalities including Growth Hormone Deficiency (“GHD”) as well as a kit comprising the necessary components of the present invention. G-protein expression and levels of mRNA are evaluated to determine if a patient has GHD or if treatment for GHD is effective. A G-protein agonist or antagonist is used to treat GHD by bringing G-protein expression and levels of mRNA into the normal range.
Methods And Compositions For Altering Behavior Associated With Autism Spectrum Disorder
Methods And Compositions For Altering Behavior Associated With Autism Spectrum Disorder
US Patent:
2011018, Jul 28, 2011
Filed:
Apr 10, 2009
Appl. No.:
12/937526
Inventors:
Jill Jacobson - Kansas City MO, US
Kathryn Ellerbeck - Kansas City KS, US
Kathryn Ellerbeck - Kansas City KS, US
Assignee:
The Children's Mercy Hospital - Kansas City MO
International Classification:
A61K 38/11, G01N 33/68, A61K 31/55, A61P 43/00
US Classification:
514 109, 436 86, 514 116, 51421301
Abstract:
The present invention discloses methods for the diagnosis and treatment of autism. The diagnostic tools provided use analysis of levels of G-protein expression, oxytocin, and vasopressin. Treatment for autism spectrum disorder and symptoms of autism spectrum disorder, especially repetitive behavior, is also provided.
Prevention Of Diabetes By Administration Of Gnrh Antagonists
Prevention Of Diabetes By Administration Of Gnrh Antagonists
US Patent:
2002010, Aug 1, 2002
Filed:
Jan 26, 2001
Appl. No.:
09/771434
Inventors:
Jill Jacobson - Kansas City MO, US
International Classification:
A61K038/10
US Classification:
514/014000
Abstract:
A method for reducing the incidence or delaying the onset of diabetes in diabetes-susceptible mammals (e.g., mice, rats, humans) is provided wherein the mammals are treated with a gonadotropin-releasing hormone (GnRH) antagonist. Preferably, the antagonist is administered repeatedly over time by subcutaneous injection. A useful antagonist is Acetyl--[2-Naphthyl]-D-Ala-D-p-Chloro-Phe--[3-Pyridyl]-D-Ala-Ser-N -[Nicotinoyl]-Lys-N -[Nicotinoyl]-D-Lys-Leu-N -[Isopropyl]-Lys-Pro-D-Ala-NH. Other useful antagonists are Nal-Glu, PPI-149 and acryline.